About FDA

Velcade (bortezomib) is Approved for Initial Treatment of Patients with Multiple Myeloma

On June 23, 2008, the U.S. Food and Drug Administration approved bortezomib for injection (Velcade, Millennium, Inc. and Johnson and Johnson Pharmaceutical Research and Development) for the treatment of patients with multiple myeloma. This approval provides clinical trial data for the use of Velcade as an initial treatment for patients with multiple myeloma. Velcade was previously approved in 2005 for the treatment of patients with multiple myeloma who had received at least one prior therapy and in 2003 for the treatment of more refractory multiple myeloma.

The current approval was based on an international, multicenter, open label, active-control trial in previously untreated patients with symptomatic multiple myeloma. Patients were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib. Patients received M (9 mg/m2 ) plus prednisone (60 mg/m2 ) daily for four days every 6 weeks or the same MP schedule with bortezomib, 1.3 mg/m2 iv on days 1, 8, 11, 22, 25, 29, and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks for 5 cycles. Time- to- progression (TTP) was the primary efficacy endpoint. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were secondary endpoints. Eligible patients were age > 65 years. A total of 682 patients were randomized: 338 to receive MP and 344 to the combination of bortezomib plus MP.  Demographics and baseline disease characteristics were similar between the two groups. 

The trial was stopped following a pre-specified interim analysis showing a statistically significant improvement in TTP with the addition of bortezomib to MP (median 20.7 months) compared with MP (median 15 months) [HR: 0.54 (95% CI: 0.42, 0.70), p= 0.000002].  OS, PFS, and RR also were significantly superior for the bortezomib-MP combination.

The most common adverse reactions (incidence >30%) in clinical studies of bortezomib include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. Dose adjustment guidelines for hematologic and neurologic toxicity are detailed in the label (package insert).

Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available frm Drugs@FDA.

Page Last Updated: 12/29/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English